Eurofins Scientific SE stock (FR0014000MR3): valuation focus as shares trade in mid-60 EUR range

Eurofins Scientific SE shares on Euronext Paris recently traded in the mid-60 EUR range, putting the France-based lab testing specialist’s valuation metrics back in focus for investors ahead of upcoming reporting dates.

Eurofins Scientific SE shares traded around the mid-60 EUR level on Euronext Paris in early June 2026, leaving the France-based testing specialist in a consolidation phase after earlier volatility.

According to Euronext quotation data as cited by Investing.com on 06/04/2026, the stock changed hands at approximately EUR 65 on the Paris exchange under the ticker ERF, reflecting a moderate recovery from levels below EUR 62 seen in May 2026, but still below prices close to EUR 69 that prevailed in mid-2025.Investing.com as of 06/04/2026

Secondary quote data compiled by StockInvest shows that on 06/04/2026 the stock gained 5.28% in a single session, moving from EUR 61.78 to EUR 65.04, highlighting ongoing price swings around the current band.StockInvest as of 06/04/2026

For German investors, the shares are also available on venues such as Tradegate through secondary listings, typically trading in euros with spreads tied closely to the Euronext Paris reference price, although liquidity remains deepest in France.

As of: 05.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Eurofins
• Sector/industry: Life sciences testing and laboratory services
• Headquarters/country: Luxembourg, France
• Core markets: Europe, North America, Asia-Pacific
• Key revenue drivers: Analytical testing services for food, environment, pharmaceutical and cosmetic products, as well as contract research
• Home exchange/listing venue: Euronext Paris (ERF)
• Trading currency: EUR

Eurofins Scientific SE: core business model

Eurofins Scientific SE focuses on providing specialized analytical testing and laboratory services to clients in regulated industries, with revenues largely generated from recurring testing contracts in areas such as food safety, environmental monitoring, and pharmaceutical quality control.

Valuation metrics and multiples for Eurofins Scientific SE

With the Eurofins Scientific SE share price around the mid-60 EUR level on 06/04/2026, valuation ratios such as price-to-earnings and enterprise-value-to-EBITDA remain key benchmarks for investors, even though detailed, up-to-the-minute multiples depend on the company’s latest reported earnings and balance sheet.

MarketScreener data referencing the company’s earlier financial disclosures indicates that Eurofins generated revenues of roughly EUR 6.7 billion in 2021, serving as a base for historical valuation comparisons as investors assess how the group’s earnings profile has evolved since the peak of pandemic-related testing demand.NCBiotech careers profile citing 2021 figures

Against that revenue backdrop, current share levels imply a market capitalization in the mid-single-digit billions of euros, so traditional multiples will be influenced by management’s ability to sustain margins in core segments like food and pharma testing while offsetting normalization effects in areas that benefited from exceptional pandemic volumes.

Income-focused investors also track Eurofins through the lens of dividend policy, with any cash distributions and payout ratios relative to earnings affecting how the stock screens versus other life sciences and laboratory peers, although the main emphasis for many shareholders remains on long-term growth and reinvestment.

Conclusion

Eurofins Scientific SE’s share price in the mid-60 EUR band on Euronext Paris keeps the spotlight on how the group’s earnings and cash flows support its current valuation. Historical revenue levels around EUR 6.7 billion in 2021 provide a reference point for investors evaluating the company’s trajectory as pandemic effects fade, especially in comparison with other life sciences testing peers.

Going forward, the market will likely focus on management’s ability to sustain growth in core analytical testing services, maintain profitability, and deploy capital efficiently, all of which will influence where Eurofins Scientific SE ultimately trades within its valuation range relative to sector benchmarks.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.